drugset
drugset / Trial / NCT04120623

Therapeutic Effect of Dapagliflozin Combined With CSII on Newly Diagnosed Type 2 Diabetes Mellitus

NCT04120623 ↗

Phase 4 Unknown 100 enrolled Nanjing First Hospital, Nanjing Medical University
RandomizedParallel-groupSingle-blindTreatment

Summary

To compare the effect of dapagliflozin combined with CSII and CSII alone on glucose profile in newly diagnosed type 2 diabetes mellitus by continuous glucose monitoring system.

Timeline

Start
2019-10-01
Primary completion
2019-12-31
Completion
2020-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 10 mg —
Comparator insulin aspart Protein / enzyme biologic — Subcutaneous

Indications

type 2 diabetes mellitus